RENATO CORPORATION TO RE-ALLOCATE INVESTMENT FUNDS TO BUILD BIOTECH MANUFACTURING FACILITIES IN SOUTH AMERICA
Miami, Fla.—October 27, 2009-Renato Corporation (DE:4OZ)—after considerable evaluation the company has decided to re-allocate the funds it recently intended to use to acquire an interest in Vanguard Pharmaceutical Corporation. The monies will now be used to develop an internal infrastructure to facilitate the building of biotech manufacturing facilities in South America.
The decision will provide the company with controlled ownership and higher returns on profit of sales acquired from the biotech generic drug manufacturing facilities. Renato will actively pursue companies who are interested in joint venture marketing agreements to operate the facilities in selective areas of South America.
www.renatocorp.com
About Renato Corporation
Renato Corporation has decisively positioned itself to provide advanced diagnostic care via private clinics and health and wellness centers here in North America, and internationally. In addition the company is broadening its business base building generic pharmaceutical facilities in developing countries.
Our professionally staffed clinics will be equipped with the latest non invasive diagnostic devices available to date. Renato Corporation will ensure that non-invasive diagnostic technologies such as Thermography and Electronic Beam Tomography (EBT) body scanning will be accessible to the general public.
At Renato Corporation, it is our pledge to continually seek out the latest innovative advanced medical diagnostic technologies available to continually provide the very best affordable private health care to our clients.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
